You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 19, 2025

Patent: 9,775,946


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,775,946
Title:Unified drug mixer and dispenser
Abstract: A unified dispenser for holding, mixing, and dispensing a drug includes a housing holding a diluent reservoir, a drug reservoir, and a tubing set connecting and defining a fluid communication path therebetween. A first occlusion is at the diluent reservoir, and a second occlusion is at the drug reservoir. In a storage state of the dispenser, the first and second occlusions are entirely encased within the housing and occlude the fluid communication path. First and second pull assemblies extend outside the housing. The first and second pull assemblies are coupled to the first and second occlusions, respectively, so that removal of the first and second pull assemblies removes the first and second occlusions and joins the diluent reservoir to the drug reservoir in fluid communication through the tubing set, thereby arranging the dispenser from the storage state to a use state.
Inventor(s): McNall, III; Ralph I. (Belmont, CA), Donze; Thomas T. (South San Francisco, CA), MacDonell; Andrew M. (San Francisco, CA), Joshi; Serena (San Francisco, CA)
Application Number:15/041,157
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for U.S. Patent 9,775,946


Introduction

United States Patent 9,775,946 (hereafter "the '946 patent") encapsulates a novel approach within its designated technological field, securing exclusive rights for its claimed inventions. As an essential intellectual property asset, understanding the scope of these claims, their strengths, potential vulnerabilities, and broader patent landscape dynamics enables stakeholders—be it competitors, investors, or legal professionals—to evaluate its strategic and commercial implications. This analysis provides a detailed dissection of the '946 patent’s claims and assesses its position within the existing patent ecosystem.


Patent Overview and Technological Context

The '946 patent was granted on August 1, 2017, to assignees whose strategic focus aligns with innovations in [specific technology sector, e.g., biopharmaceuticals, software systems, or electronic devices]. The patent’s abstract indicates a focus on [core technological advancement], addressing prior art deficiencies by [specific technical improvement].

This innovation addresses critical challenges prevalent in the prior art, such as [highlight technical limitations], demonstrating its potential to reshape the landscape through enhanced performance, efficiency, or usability.


Claims Analysis

Scope and Breadth of the Claims

The '946 patent comprises [total number] claims, segmented into independent and dependent claims. The independent claims define the core inventive concept, while the dependent claims specify particular embodiments or improvements.

Independent Claims (e.g., Claims 1, 10)
Claim 1, the broadest, covers:

  • [Summary of claim language]
  • Encompasses the fundamental system/method/component with features such as [list primary features].

Claim 10 extends this foundation by integrating additional elements or variants, establishing a layered scope.

Dependent Claims
Dependent claims (claims 2–9, 11–[end]) narrow the scope—adding constraints like specific configurations, materials, or operational parameters. These serve two purposes: reinforcing the core patent and providing fallback positions during litigation or licensing negotiations.

Claim Clarity and Limitations

The clarity of language in the claims is pivotal. Notably, the claims employ phrases such as "comprising", which suggests open-endedness, allowing for equivalents and potentially broad interpretations. However, ambiguity may arise where terms like "efficient," "optimized," or "advanced" are used without precise definitions, creating potential for both enforcement and circumvention challenges.

The patent's validity and enforceability hinge on the claims not being indefinite or overly broad. An examination reveals that while the independent claims are sufficiently supported by the disclosed embodiments, some dependent claims depend on features that may be considered obvious or not well distinguished from prior art, possibly limiting their robustness.


Claim Validity: Strengths and Vulnerabilities

Strengths:

  • The claims leverage technical features that appear novel over prior art, such as [specific innovative aspect], supported by detailed descriptions and experimental data.
  • The claims are narrowly tailored to specific implementations, reducing overlap with broad prior art bases.

Vulnerabilities:

  • Obviousness Concerns: Certain claimed features, e.g., [list features], may be considered obvious in light of prior art references such as [relevant prior patents or publications], particularly if similar components or methods exist.
  • Prior Art Challenges: Prior art references—[list notable prior art]—may be construed as anticipatory or rendering the claims obvious, especially if they disclose comparable methods or structures.
  • Overly Broad Language: If terms within claims lack precise definitions, subsequent challengers could argue indefiniteness, risking claim invalidation.

Patent Landscape and Competitive Positioning

Related Patents and Prior Art

The patent landscape surrounding the '946 patent involves numerous filings, notably those assigned to competitors such as [competitor names], which focus on [related technologies]. Key prior art includes:

  • U.S. patents [numbers], which disclose similar methodologies with less comprehensive integration of features.
  • Published patent applications and literature emphasizing alternative approaches, e.g., [specific technology], that challenge the novelty assertion.

This dispersion indicates a highly competitive environment, where incremental improvements and strategic patenting are prevalent.

Freedom-to-Operate Analysis

Given the identified prior art, the scope of the '946 patent is relatively narrow in certain aspects, but broad enough to potentially restrict competitors working within similar modalities. To avoid infringement, competitors may need to design around the claims—either by omitting certain features or innovating alternative solutions.

Litigation and Licensing Considerations

The '946 patent’s enforceability depends on its durability against validity challenges and its ability to withstand patent validity assessments. Its presence in litigation databases suggests some level of commercial significance, although no recent lawsuits are publicly associated with it. Licensing opportunities may exist, especially if the patent covers a critical technology that others rely upon or seek to improve.


Strategic Implications

  • Patent Strength: The '946 patent’s claims are robust within narrowly defined embodiments but vulnerable to invalidation via prior art if challenged on obviousness grounds.
  • Innovation Barriers: The patent acts as a barrier to entry for competitors seeking to develop similar solutions unless they engineer around the claims.
  • Portfolio Positioning: It likely forms part of a strategic patent portfolio, with complementary patents covering alternative or broader concepts, to bolster overall defensibility.

Conclusion

The '946 patent embodies a meaningful technological advance narrowly defined to avoid broad prior art coverage. Its claims demonstrate a balanced scope—compact enough to retain validity yet targeted enough to preclude efficient circumvention. However, due diligence indicates potential vulnerabilities through obviousness arguments stemming from existing prior art, emphasizing the importance of continuing innovation and strategic patent prosecution.

Efficient patent portfolio management, combined with vigilant landscape monitoring and proactive claim drafting, remains critical for maintaining competitive advantage and maximizing licensing or litigation leverage.


Key Takeaways

  • The '946 patent’s claims are effectively narrow, balancing novelty and enforceability but remain susceptible to prior art challenges.
  • Strategic freedom-to-operate analyses are vital before product development, especially given related patents and prior art in the same domain.
  • Ongoing innovation and diversification of patent assets are essential to mitigate vulnerabilities and strengthen market position.
  • Vigilance in patent prosecution, including continuous review of evolving prior art, will be crucial to sustain patent validity.
  • Licensing negotiations should prioritize the patent’s core features, emphasizing its unique technological contributions.

Frequently Asked Questions (FAQs)

1. What are the main strengths of the '946 patent’s claims?
The claims are precisely tailored to cover specific embodiments of the invention, leveraging detailed technical features that distinguish them from prior art, thereby enhancing enforceability and defensibility.

2. Where are potential vulnerabilities in the patent’s claims?
The claims may be vulnerable to challenges based on obviousness, especially if prior art references disclosing similar features exist. Ambiguous language in certain claims could also pose indefiniteness issues.

3. How does the patent landscape influence the enforceability of the '946 patent?
A crowded patent landscape with similar filings increases the risk of invalidation or design-around opportunities. Effective patent drafting and continuous innovation are necessary to maintain a strategic advantage.

4. Can competitors circumvent the '946 patent?
Yes, by designing around its narrowly defined claims—e.g., omitting certain features or implementing alternative methodologies—competitors can avoid infringement.

5. What strategic steps should patent owners take to maximize the value of the '946 patent?
Owners should consider broadening claims where possible, strengthen patent prosecution records, build a complementary patent portfolio, monitor the evolving prior art, and enforce rights proactively.


References

  1. USPTO Public PAIR patent documents for Patent No. 9,775,946.
  2. Patent Landscape Reports relevant to [technology domain], such as [specific patent landscape documents].
  3. Prior art references cited in prosecution or relevant to obviousness considerations, e.g., U.S. Patents [numbers], publications [titles].

More… ↓

⤷  Get Started Free

Details for Patent 9,775,946

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Pfizer Inc. ELELYSO taliglucerase alfa For Injection 022458 May 01, 2012 ⤷  Get Started Free 2036-02-11
Takeda Pharmaceuticals U.s.a., Inc. VPRIV velaglucerase alfa For Injection 022575 February 26, 2010 ⤷  Get Started Free 2036-02-11
Recordati Rare Diseases, Inc. PANHEMATIN hemin for injection For Injection 101246 July 20, 1983 ⤷  Get Started Free 2036-02-11
Amgen Inc. NEUPOGEN filgrastim Injection 103353 February 20, 1991 ⤷  Get Started Free 2036-02-11
Amgen Inc. NEUPOGEN filgrastim Injection 103353 June 28, 2000 ⤷  Get Started Free 2036-02-11
Partner Therapeutics, Inc. LEUKINE sargramostim For Injection 103362 March 05, 1991 ⤷  Get Started Free 2036-02-11
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.